Catalent’s iPSCs as a Starting Material for Advanced Cell Therapies

(1:44)

Catalent’s Comprehensive Cell Therapy Portfolio

(5:59)

Catalent in 30 Seconds

(31)

What's the Deal with Induced Pleuripotent Stem Cells (iPSCs)?

(16:58)

NBR in conversation with Catalent

(12:11)

Achieving clinical quality for human iPSC generation and expansion

(28:6)

Site Tour of Catalent Gosselies

(3:30)

Catalent Senior Executives Announce Leadership Transition

(4:51)

Modeling the human brain using induced pluripotent stem cells iPSCs

(1:6:10)

Site Tour of Catalent’s Swindon, UK Facility

(8:29)

Catalent Bloomington, IN – Flexible Filling Line

(4:19)

Overcoming challenges in scaled manufacturing of iPSC-derived cells [WEBINAR]

(45:14)

Our Values

(5:8)

A Guide to Passaging Human Pluripotent Stem Cells Using mTeSR®1

(5:58)

Catalent Limoges : du remplissage de seringues aux essais cliniques

(2:38)

Site Tour of Catalent’s Madison, WI Facility

(6:48)

Site Tour of Catalent Buenos Aires

(4:47)

Catalent Cell Therapy Capabilities

(1:55)

Careers at Catalent Biologics

(1:48)

CAR-T Therapy: An Integrated Approach with an Experienced Partner

(2:14)

Passaging iPSCs

(6:6)

Introducing Catalent Xpress Pharmaceutics™ - Facilitate Adaptive Trials and Accelerate Phase 1

(3:2)

Induced Pluripotent Stem Cells (iPSCs)

(2:18)

Catalent to Acquire Gene Therapy Leader, Paragon Bioservices, Inc.

(2:34)

Why Choose Catalent To Launch Your Next Biologics in Europe?

(1:19)

Achieving clinical quality for human iPSC generation and expansion

(43:44)

Biologics Development Overview | Why Catalent?

(23)

GPEx® Boost: The Next Generation of Cell Line Development

(1:40)